Company Watch

Dabur Pharma divests domestic non-oncology business

Our News Bureau - Mumbai

Dabur Pharma, announced the sale of its domestic non-oncology formulations business to Alembic. The move is in line with Dabur Pharma's strategy to focus on its core oncology business and exit other non-core businesses. "While the non-oncology formulations has been a growing business for us, this divestiture would allow us to increase our focus and investment in building a world class global oncology business which we believe offers greater long-term value for Dabur Pharma's shareholders," said Dr Anand Burman, Chairman, Dabur Pharma.

He also indicated that in the future, the company would increasingly focus on its competencies in oncology and on expanding the research and generics portfolio in this area. "Leveraging our core competencies and focusing our resources and energies in the oncology business that we believe has the greatest growth potential has been the driving force behind this move," said Ajay Vij, COO, Dabur Pharma. "Oncology is the most valuable and strategically important business in Dabur Pharma's business portfolio. It is integral to our long-term strategy and we continue to align the business so as to build on our leadership position in the global oncology market," he added.

"We are excited to take up Dabur Pharma's fast growing portfolio in the gynaecology, cardio and diabetes product segments. Its existing product portfolio combined with the future growth opportunities provide excellent synergistic value to us," said Chirayu R Amin of Alembic. He further added that Alembic was committed to growing and strengthening the business while facilitating even better support to the healthcare providers and the patient community.